Literature DB >> 19571619

Prevalence of the extended-spectrum beta-lactamase and qnr genes in clinical isolates of Escherichia coli.

Yongjung Park1, Hyun Kyung Kang, Il Kwon Bae, Juwon Kim, Jae Seok Kim, Young Uh, Seok Hoon Jeong, Kyungwon Lee.   

Abstract

BACKGROUND: This study was performed to investigate the prevalence of qnr genes in clinical isolates of Escherichia coli from Korea that produce extended-spectrum beta-lactamases (ESBLs).
METHODS: During the period of May to June 2005, we collected clinical isolates of E. coli that were intermediate or resistant to ceftazidime and/or cefotaxime from 11 Korean hospitals. Antimicrobial susceptibility was determined by the disk diffusion and agar dilution methods. ESBL production was confirmed phenotypically by the double-disk synergy test. ESBL and qnr genes were searched for by PCR amplification, and the PCR products were then subjected to direct sequencing.
RESULTS: Double-disk synergy tests were positive in 84.3% (118/140) of ceftazidime- and/or cefotaxime-nonsusceptible E. coli isolates. The most prevalent types of ESBL in E. coli isolates were CTX-M-14 (N=41) and CTX-M-15 (N=58). Other ESBLs were also identified, including CTX-M-3 (N=7), CTX-M-9 (N=8), CTX-M-12 (N=1), CTX-M-57 (N=1), SHV-2a (N=2), SHV-12 (N=17) and TEM-52 (N=4). The qnrA1 and qnrB4 genes were identified in 4 and 7 ESBL-producing isolates, respectively.
CONCLUSIONS: CTX-M-type enzymes were the most common type of ESBL in E. coli isolates from Korea, and the qnr genes were not uncommon in ESBL-producing E. coli isolates. Dissemination of E. coli containing both ESBL and qnr genes could compromise the future usefulness of the expanded-spectrum antibiotics for the treatment of infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571619     DOI: 10.3343/kjlm.2009.29.3.218

Source DB:  PubMed          Journal:  Korean J Lab Med        ISSN: 1598-6535


  6 in total

1.  Dissemination of Extended-Spectrum β-Lactamases and Quinolone Resistance Genes Among Clinical Isolates of Uropathogenic Escherichia coli in Children.

Authors:  Iraj Sedighi; Mohammad Reza Arabestani; Ali Rahimbakhsh; Zahra Karimitabar; Mohammad Yousef Alikhani
Journal:  Jundishapur J Microbiol       Date:  2015-07-25       Impact factor: 0.747

2.  Prevalence of Quinolone Resistance Among Extended-Spectrum β -Lactamase Producing Uropathogenic Klebsiella pneumoniae.

Authors:  Fereshteh Raei; Fereshteh Eftekhar; Mohammad Mehdi Feizabadi
Journal:  Jundishapur J Microbiol       Date:  2014-06-01       Impact factor: 0.747

3.  The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.

Authors:  Jin Young Ahn; Hea Won Ann; Yongduk Jeon; Mi Young Ahn; Dong Hyun Oh; Yong Chan Kim; Eun Jin Kim; Je Eun Song; In Young Jung; Moo Hyun Kim; Wooyoung Jeong; Nam Su Ku; Su Jin Jeong; Jun Yong Choi; Dongeun Yong; Young Goo Song; June Myung Kim
Journal:  BMC Infect Dis       Date:  2017-05-03       Impact factor: 3.090

4.  Frequency of quinolone resistance genes among extended-spectrum β-lactamase (ESBL)-producing Escherichia coli strains isolated from urinary tract infections.

Authors:  Ahmad FarajzadehSheikh; Hojat Veisi; Mojtaba Shahin; Muhammad Getso; Abbas Farahani
Journal:  Trop Med Health       Date:  2019-03-04

5.  qnr Prevalence in Extended Spectrum Beta-lactamases (ESBLs) and None-ESBLs Producing Escherichia coli Isolated from Urinary Tract Infections in Central of Iran.

Authors:  Iraj Pakzad; Sohbhan Ghafourian; Morovat Taherikalani; Norkhoda Sadeghifard; Hamid Abtahi; Mohammad Rahbar; Neda Mansory Jamshidi
Journal:  Iran J Basic Med Sci       Date:  2011-09       Impact factor: 2.699

6.  CTX-M-55-type extended-spectrum β-lactamase-producing Shigella sonnei isolated from a Korean patient who had travelled to China.

Authors:  Wonmok Lee; Hae-Sun Chung; Hyukmin Lee; Jong Hwa Yum; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee; Yunsop Chong
Journal:  Ann Lab Med       Date:  2013-02-21       Impact factor: 3.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.